Can Hematological Inflammatory Parameters Predict Mortality in Hepatocellular Carcinoma?

Area of Science:

• Hepatocellular Carcinoma Research
• Oncology Biomarkers
• Inflammatory Markers in Cancer

Background:

• Hepatocellular carcinoma (HCC) is a prevalent and aggressive malignancy.
• Inflammatory and hematological parameters, including neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR), offer prognostic insights in various cancers.
• The utility of NLR and PLR in predicting outcomes for HCC patients requires further elucidation.

Purpose of the Study:

• To assess the efficacy of neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) in evaluating the prognosis of hepatocellular carcinoma (HCC) patients.
• To investigate the correlation between NLR and PLR levels and mortality in HCC.
• To determine the predictive value of these inflammatory markers in conjunction with established staging systems.

Main Methods:

• A prospective observational cohort study was conducted.
• 105 patients diagnosed with HCC based on cirrhosis were included.
• Patients were staged using the Barcelona Clinic Liver Cancer (BCLC) system, Okuda staging, and Milan criteria.

Main Results:

• The study included 105 patients (73.3% male, mean age 60.6 years).
• Higher NLR (>2.7) and PLR (>100.29) levels, advanced BCLC and Okuda stages, and failure to meet Milan criteria were associated with shorter survival.
• Neutrophil/lymphocyte ratio (NLR) >2.7, advanced BCLC stage, and Child C classification independently predicted mortality.

Conclusions:

• A significant correlation exists between elevated NLR-PLR levels and increased mortality in HCC patients.
• Neutrophil/lymphocyte ratio (NLR) and platelet/lymphocyte ratio (PLR) can serve as valuable adjuncts to existing staging systems for monitoring and predicting HCC survival.
• These inflammatory markers offer potential for improved prognostic assessment in hepatocellular carcinoma management.